VXRT - Vaxart, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
VXRT price evolution
VXRT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.48 | $43.28 | $26.73 | $34.76 |
| Short term investments | $19.31 | $9.93 | $4.96 | |
| Net receivables | $3.68 | $4.78 | $0.56 | $3.01 |
| Inventory | ||||
| Total current assets | $66.46 | $71.53 | $44.28 | $45.54 |
| Long term investments | ||||
| Property, plant & equipment | $31.01 | $32.93 | $34.85 | $36.57 |
| Goodwill & intangible assets | $8.43 | $8.61 | $8.8 | |
| Total noncurrent assets | $42.21 | $44.39 | $46.29 | |
| Total investments | $19.31 | $9.93 | $4.96 | |
| Total assets | $166.67 | $113.75 | $88.67 | $91.83 |
| Current liabilities | ||||
| Accounts payable | $2.52 | $3.59 | $3.98 | $1.58 |
| Deferred revenue | ||||
| Short long term debt | $2.87 | $2.8 | $2.7 | |
| Total current liabilities | $80.36 | $15.76 | $14.12 | $13.72 |
| Long term debt | $2.13 | $15.98 | $16.69 | $17.39 |
| Total noncurrent liabilities | $17.98 | $18.86 | $20.3 | |
| Total debt | $18.86 | $19.49 | $20.09 | |
| Total liabilities | $98.23 | $33.73 | $32.98 | $34.02 |
| Shareholders' equity | ||||
| Retained earnings | -$464.54 | -$450.46 | -$433.99 | -$409.57 |
| Other shareholder equity | $0.03 | -$0.02 | -$0.01 | -$0 |
| Total shareholder equity | $80.01 | $55.69 | $57.8 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.76 | $15.18 | $143.75 | $126.87 |
| Short term investments | $4.96 | $49.7 | $22.74 | |
| Net receivables | $3.01 | $0.02 | $0.07 | $0.33 |
| Inventory | ||||
| Total current assets | $45.54 | $99.45 | $169.17 | $128.53 |
| Long term investments | $16.21 | |||
| Property, plant & equipment | $36.57 | $41.3 | $19.77 | $8.32 |
| Goodwill & intangible assets | $8.8 | $9.53 | $15.13 | $15.36 |
| Total noncurrent assets | $46.29 | $54.4 | $52 | $24.05 |
| Total investments | $4.96 | $49.7 | $38.95 | |
| Total assets | $91.83 | $153.85 | $221.17 | $152.58 |
| Current liabilities | ||||
| Accounts payable | $1.58 | $5.51 | $3.87 | $2.13 |
| Deferred revenue | $2 | |||
| Short long term debt | $2.7 | $2.23 | $1.01 | $2.05 |
| Total current liabilities | $13.72 | $17.92 | $10.78 | $11.76 |
| Long term debt | $17.39 | $19.48 | $12 | $5.16 |
| Total noncurrent liabilities | $20.3 | $25.33 | $22.85 | $17.41 |
| Total debt | $20.09 | $21.7 | $13.01 | $7.21 |
| Total liabilities | $34.02 | $43.25 | $33.64 | $29.18 |
| Shareholders' equity | ||||
| Retained earnings | -$409.57 | -$327.11 | -$219.35 | -$148.88 |
| Other shareholder equity | -$0 | -$0.3 | -$0.07 | |
| Total shareholder equity | $57.8 | $110.6 | $187.53 | $123.4 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.93 | $6.4 | $2.18 | $3.25 |
| Cost of revenue | ||||
| Gross Profit | $6.4 | $2.18 | $3.25 | |
| Operating activities | ||||
| Research & development | $17.48 | $19.01 | $14.71 | |
| Selling, general & administrative | $5.18 | $7.24 | $5.44 | |
| Total operating expenses | $19.41 | $22.66 | $26.25 | $20.14 |
| Operating income | -$16.26 | -$24.07 | -$16.9 | |
| Income from continuing operations | ||||
| EBIT | -$16.45 | -$24.37 | -$17.2 | |
| Income tax expense | $0.02 | $0.02 | $0.04 | $0.17 |
| Interest expense | $0.41 | |||
| Net income | ||||
| Net income | -$14.08 | -$16.47 | -$24.42 | -$17.38 |
| Income (for common shares) | -$16.47 | -$24.42 | -$17.38 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.38 | $0.11 | $0.89 | $4.05 |
| Cost of revenue | ||||
| Gross Profit | $7.38 | $0.11 | $0.89 | $4.05 |
| Operating activities | ||||
| Research & development | $68.14 | $81.05 | $48.75 | $19.86 |
| Selling, general & administrative | $22.58 | $29.39 | $21.89 | $15.2 |
| Total operating expenses | $90.73 | $114.69 | $73.64 | $34.22 |
| Operating income | -$83.35 | -$114.59 | -$72.75 | -$30.17 |
| Income from continuing operations | ||||
| EBIT | -$82.2 | -$107.69 | -$70.36 | -$31.98 |
| Income tax expense | $0.26 | $0.07 | $0.11 | $0.24 |
| Interest expense | $1.87 | |||
| Net income | ||||
| Net income | -$82.47 | -$107.76 | -$70.47 | -$32.22 |
| Income (for common shares) | -$82.47 | -$107.76 | -$70.47 | -$32.22 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$16.47 | -$24.42 | -$17.38 | |
| Operating activities | ||||
| Depreciation | $2.21 | $2.18 | $2.33 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.56 | $4.12 | $3.71 | |
| Total cash flows from operations | -$12.03 | -$21.19 | -$13.52 | |
| Investing activities | ||||
| Capital expenditures | -$0.37 | -$0.13 | $0.1 | |
| Investments | -$9.29 | -$4.89 | $15 | |
| Total cash flows from investing | -$31.73 | -$9.66 | -$5.02 | $15.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $38.26 | $18.38 | $0.26 | |
| Net borrowings | ||||
| Total cash flows from financing | $56.43 | $38.24 | $18.2 | -$0.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$12.72 | $16.55 | -$8.02 | $1.52 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$82.47 | -$107.76 | -$70.47 | -$32.22 |
| Operating activities | ||||
| Depreciation | $8.62 | $5.8 | $4.21 | $2.71 |
| Business acquisitions & disposals | -$4.83 | |||
| Stock-based compensation | $14.13 | $13.59 | $8.87 | $4.36 |
| Total cash flows from operations | -$70.45 | -$94.78 | -$59.83 | -$23.75 |
| Investing activities | ||||
| Capital expenditures | -$1.75 | -$9.6 | -$5.16 | -$1.22 |
| Investments | $45.7 | -$10.81 | -$39.11 | |
| Total cash flows from investing | $43.95 | -$20.41 | -$49.1 | -$1.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.61 | $17.46 | $125.8 | $137.66 |
| Net borrowings | ||||
| Total cash flows from financing | $15.24 | $17.46 | $125.8 | $138.31 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.26 | -$97.73 | $16.88 | $113.34 |
News
Fundamentals
| Market cap | $70.52M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 227.48M |
| Revenue | $16.76M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$72.34M |
| Revenue Q/Q | 134.79% |
| Revenue Y/Y | 303.27% |
| P/E ratio | -0.97 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 4.21 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.02 |
| EPS | -$0.32 |
|---|---|
| ROA | -62.78% |
| ROE | N/A |
| Debt/Equity | 0.59 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.83 |
| Quick ratio | N/A |